Diet-microbiota related inflammatory conditions such as obesity, autoimmune type 1 diabetes (T1D), type 2 diabetes (T2D), cardiovascular disease (CVD) and gut infections have become a stigma in Western societies and developing nations. This book chapter examines the most relevant pre-clinical and clinical studies about diet-gut microbiota approaches as an alternative therapy for diabetes. We also discuss what we and others have extensively investigated- the power of dietary short-chain fatty acids (SCFAs) technology that naturally targets the gut microbiota as an alternative method to prevent and treat diabetes and its related complications.
CITATION STYLE
Yap, Y. A., & Mariño, E. (2021). Dietary SCFAs Immunotherapy: Reshaping the Gut Microbiota in Diabetes. In Advances in Experimental Medicine and Biology (Vol. 1307, pp. 499–519). Springer. https://doi.org/10.1007/5584_2020_515
Mendeley helps you to discover research relevant for your work.